Side by side: size, value over time, results, valuation, margins, growth, debt and shareholder returns, and any of thirty figures charted over the years (up to 6).
Open these as a peer group: up to 12 companies with suggested peers, each company's rank in the group and percentile in its sector and country, saved for you or your team.
From Jan 2020: how each company's value moved, whatever its size.
US$ billions, as reported in each year's annual results.
Revenue of the fiscal year. US dollars at each year's exchange rate.
| Measure | DexCom, Inc.✕ DXCM · #854 in the world | Quest Diagnostics Incorporated✕ DGX · #902 in the world |
|---|---|---|
| Profile | ||
| Country | 🇺🇸 USA | 🇺🇸 USA |
| Sector | Healthcare | Healthcare |
| Industry | Diagnostics and Research | Diagnostics and Research |
| Founded | 1999 | 1967 |
| Size | ||
| Market cap | ||
The largest companies, each against its nearest peers in value from the same industry.
| Fiscal year | DexCom, Inc. | Quest Diagnostics Incorporated |
|---|---|---|
| 2025 | $4.7 BSEC | $11.0 BSEC |
| 2024 | $4.0 BSEC | $9.9 BSEC |
| 2023 | $3.6 BSEC | $9.3 BSEC |
| 2022 | $2.9 BSEC | $9.9 BSEC |
| 2021 | $2.4 BSEC | $10.8 BSEC |
| 2020 | $1.9 BSEC | $9.4 BSEC |
| 2019 | $1.5 BSEC | $7.7 BSEC |
| 2018 | $1.0 BSEC | $7.5 BSEC |
| 2017 | $719 MSEC | $7.4 BSEC |
| 2016 | $573 MSEC | $7.2 BSEC |
| 2015 | $402 MSEC | $7.5 BSEC |
| 2014 | $259 MSEC | $7.4 BSEC |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports; Ed. = the company's report (editors); WD = Wikidata, citing the annual report; Cap = value.today market caps. Hover a figure for its period.
| $29.9 B |
| $27.8 B |
| Revenue | $4.7 B | $11.0 B |
|---|
| Net income | $836 M | $992 M▲ best |
|---|
| Employees | 11,100 | 57,000 |
|---|
| Valuation | ||
|---|---|---|
| P/E ratio | 30.2× | 24.6× |
| Price to sales | 5.9× | 2.4× |
| Price to book | 10.9× | 3.9× |
| Free cash flow yield | 3.6% | 4.9%▲ best |
| Profitability | ||
|---|---|---|
| Gross margin | 60.1%▲ best | 33.2% |
| Operating margin | 19.6%▲ best | 14.1% |
| Net margin | 17.9%▲ best | 9.0% |
| Return on equity | 34.5%▲ best | 14.2% |
| Return on invested capital | — | 9.5% |
| Growth | ||
|---|---|---|
| Revenue growth | 15.6%▲ best | 11.8% |
| Revenue growth, 3 years a year | 17.0%▲ best | 3.7% |
| Earnings per share growth | 47.2%▲ best | 13.8% |
| Financial strength | ||
|---|---|---|
| Debt to equity | — | 0.8× |
| Net debt to EBITDA | — | 2.5× |
| Interest cover | 63.8× | — |
| Cash | ||
|---|---|---|
| Free cash flow margin | 23.1%▲ best | 12.3% |
| Shareholder returns | ||
|---|---|---|
| Dividend yield | — | 1.3% |
| Shareholder yield | 1.7% | 2.9%▲ best |
| Strength scores | ||
|---|---|---|
| Piotroski F-score | — | 8 of 9 |
| Altman Z-score zone | safe | safe |
|---|
| Data as of | Market cap Oct 2026; ratios FY2025 | Market cap Oct 2026; ratios FY2025 |
|---|
Market caps from exchange data or SEC filings on the date shown (* last known value, no current one); revenue and net income from the latest annual results; ratios worked out from each company's own statements for the fiscal year shown. ▲ marks the best of these companies where higher or lower is better; size and valuation multiples are marked for no one. Definitions: methodology.